Updates in the management of twin-to-twin transfusion syndrome

Twin-to-twin transfusion syndrome (TTTS) is a serious complication of monochorionic twin pregnancy. Shared placental vascular connections can create an uneven circulation, causing one fetus to become the donor and the other the recipient. The donor may develop reduced urine production and oligohydramnios, while the recipient can develop polyhydramnios, cardiac strain, and fluid overload.

Management has changed substantially as fetal imaging, laser surgery, anesthesia, and neonatal care have improved. The central principles remain early recognition, careful staging, referral to a specialist fetal medicine unit, and treatment matched to gestational age and disease severity.

The subject has long been central to international perinatal medicine and research. The FAOPS 2020 archive reflects the scientific setting in which clinicians and researchers shared developments in fetal therapy, neonatal medicine, and pregnancy outcomes.

Why surveillance matters in monochorionic twins

TTTS occurs almost exclusively in monochorionic diamniotic twins, who share a placenta but have separate amniotic sacs. Vascular anastomoses within the placenta allow blood to pass between the fetal circulations. When the net flow becomes persistently unbalanced, the donor and recipient develop different patterns of illness.

Routine surveillance is designed to identify these changes before irreversible organ damage occurs. Most specialist protocols begin ultrasound assessment around 16 weeks for monochorionic pregnancies, with examinations at least every two weeks. The scan should assess amniotic fluid in both sacs, bladder visibility, fetal growth, Doppler findings, and signs of hydrops or cardiac dysfunction.

A sudden increase in abdominal size, breathlessness, pelvic pressure, or reduced fetal movement may prompt an urgent assessment, although symptoms can be absent. Ultrasound remains the essential diagnostic tool. Maternal symptoms alone cannot establish or exclude twin-to-twin transfusion.

Staging and diagnostic assessment

The Quintero staging system remains a useful clinical framework. Stage I generally involves polyhydramnios in the recipient and oligohydramnios in the donor, with the donor bladder still visible. In stage II, the donor bladder is no longer visible during the examination. Stage III includes abnormal Doppler studies, such as absent or reversed end-diastolic flow in the umbilical artery, absent or reversed flow in the ductus venosus, or pulsatile flow in the recipient’s umbilical vein.

Stage IV is defined by hydrops in one or both fetuses. Stage V refers to the death of one or both fetuses. Staging supports communication and treatment planning, but it does not capture every clinically important feature. A rapidly progressive stage I case, for example, may need more urgent review than a stable case with the same nominal stage.

Assessment should include fetal echocardiography when indicated, particularly if the recipient shows cardiomegaly, tricuspid regurgitation, abnormal venous Doppler findings, or other evidence of cardiac stress. The specialist team also considers cervical length, placental location, gestational age, fetal growth discordance, and the possibility of related conditions such as twin anemia-polycythemia sequence.

Selecting treatment according to disease severity

Management depends on stage, gestational age, rate of progression, fetal condition, and available expertise. Stable stage I disease may sometimes be monitored closely, especially when the diagnosis is recent and both fetuses have reassuring findings. Frequent review is essential because progression can occur quickly.

Fetoscopic laser photocoagulation is the standard definitive treatment for significant TTTS in the mid-trimester. During the procedure, a fetoscope is introduced into the recipient’s amniotic sac, the shared placental vessels are identified, and communicating vessels are sealed with laser energy. This separates the circulations and addresses the underlying cause rather than temporarily removing excess fluid.

Amnioreduction, also called therapeutic amniocentesis, removes fluid from the recipient’s sac. It can reduce maternal discomfort and uterine distension and may be used when laser therapy is unavailable, technically unsuitable, or inappropriate for the clinical circumstances. However, it does not eliminate the placental connections, so the risk of recurrence or ongoing imbalance remains.

Evidence generally favors laser therapy over serial amnioreduction for appropriate mid-trimester cases because laser treatment improves the chance of survival without severe neurological impairment in at least one twin. The exact benefit varies with stage, gestational age, center experience, and the condition of the fetuses before treatment.

How fetoscopic laser therapy is performed

Before surgery, the team reviews ultrasound and Doppler findings, maps the placenta, explains possible outcomes, and discusses anesthesia and preterm birth risks. The procedure is usually performed under maternal regional or local anesthesia with sedation, although practice varies. Ultrasound guidance is used to place the fetoscope through the maternal abdomen and uterus.

The surgeon identifies the vascular equator, where vessels cross between the territories of the two fetuses. Communicating arteries and veins are coagulated. Many centers use a Solomon technique, adding a line of laser coagulation between treated vessels to reduce the risk of residual small connections. The recipient’s excess amniotic fluid is then reduced to an appropriate level.

Possible complications include preterm premature rupture of membranes, bleeding, infection, placental abruption, fetal injury, recurrent TTTS, twin anemia-polycythemia sequence, and loss of one or both fetuses. The procedure can also lead to a complicated course if one twin dies, because the surviving twin may be exposed to acute blood loss through the shared circulation.

The goal is to improve the outlook for both fetuses, but treatment cannot guarantee survival or normal development. Families should receive individualized estimates based on stage, gestational age, fetal cardiac function, hydrops, and the experience of the referral center.

Follow-up after fetal intervention

After laser surgery, ultrasound surveillance continues at regular intervals. The team checks amniotic fluid, bladder filling, fetal growth, umbilical and venous Dopplers, and signs of recurrent fluid imbalance. A scan may also identify twin anemia-polycythemia sequence, in which one twin becomes anemic and the other polycythemic through small residual vascular connections.

Neurological assessment is important because severe TTTS, fetal demise, prematurity, and hemodynamic instability can increase the risk of brain injury. Follow-up may include targeted neurosonography, fetal magnetic resonance imaging in selected cases, and structured developmental assessment after birth.

Counseling should cover delivery planning, neonatal intensive care, possible respiratory support, and the long-term need for hearing, vision, motor, and neurodevelopmental monitoring. Families may also encounter rapidly changing evidence during pregnancy. For broader perinatal counseling, the discussion of SARS-CoV-2 evidence illustrates why infection data and fetal medicine recommendations must be interpreted in the context of current research.

Delivery timing is individualized. Continuing the pregnancy can improve maturity when the fetuses remain stable, but worsening Dopplers, hydrops, growth restriction, recurrent fluid abnormalities, or maternal complications may require earlier birth. A tertiary center with fetal therapy and neonatal intensive care resources is usually preferred.

Practical priorities for clinicians and families

Because TTTS can progress between appointments, care works best when the referral pathway is defined before an abnormal scan occurs. Community obstetric teams should know which fetal medicine unit accepts urgent referrals, while families should understand the expected surveillance interval and symptoms that warrant immediate contact.

The following priorities support consistent care:

• Confirm chorionicity and amnionicity early, ideally in the first trimester.
• Begin regular ultrasound surveillance around 16 weeks for monochorionic pregnancies.
• Refer suspected TTTS promptly to a fetal medicine center with fetoscopic laser expertise.
• Use Doppler studies, fetal echocardiography, and growth assessment alongside Quintero staging.
• Arrange neonatal, neurological, and developmental follow-up after fetal therapy or preterm birth.

Communication should remain clear and balanced. Families need to understand the difference between a treatment that addresses the placental cause and one that temporarily relieves excess fluid. They also need realistic information about survival, neurological outcomes, possible complications, and the uncertainty that accompanies severe or late-stage disease.

Turning specialist evidence into timely care

The most important update in TTTS management is the growing emphasis on coordinated, stage-sensitive care. Surveillance detects the syndrome, structured assessment defines its severity, and fetoscopic laser therapy offers a way to interrupt the abnormal placental circulation when the pregnancy is suitable for intervention.

Clinicians caring for monochorionic twins should review local referral pathways, update ultrasound protocols, and discuss complex cases with a multidisciplinary fetal medicine team early. Families facing a diagnosis should seek assessment at an experienced center where fetal therapy, maternal care, neonatology, and long-term developmental follow-up are integrated. Acting promptly can preserve options and provide the clearest path through a high-risk pregnancy.